post-stephen-hill-targacept280

Targacept confirms Stephen Hill as president and chief executive

pharmafile | November 27, 2012 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Targacept, stephen hill 

Clinical-stage biopharma firm Targacept has announced that Stephen Hill has been appointed as president and chief executive.

Hill is expected to start with the company on 1 December and will also join Targacept’s Board of directors. He brings over 20 years of industry experience to the role, having served previously as president and chief executive of Solvay Pharmaceuticals, and ArQule. 

“Steve’s appointment is the culmination of a robust selection process designed to identify the right person to take the helm at Targacept and drive value creation,” said Mark Skaletsky, chairman of Targacept’s Board of directors. “Steve is a seasoned leader with an impressive background of achievement.”

Advertisement

Hill added: “I am delighted to join Targacept and look forward to working with the management team, employees and Board. I believe there is tremendous potential at Targacept to build upon a strong scientific and financial foundation and a promising clinical portfolio to deliver new treatment options to patients in need.”

Upon Hill joining Targacept, the previously formed Office of the chairman will be dissolved. “On behalf of the Board of directors, I would like to thank publicly executive team members Jeff Brennan, Alan Musso and Pete Zorn for stepping up under challenging circumstances and helping to lead Targacept over the last several months as the chief executive search was ongoing,” said Skaletsky.

Related Content

Targecept image

Targacept admits failure in Alzheimer’s trial

Targacept is dropping a once promising Alzheimer’s drug from further clinical trials after it failed …

AstraZeneca to take Alzheimer’s drug into phase II

AstraZeneca is to continue the development of Targacept’s AZD1446 as a treatment for Alzheimer’s disease.AZD1446 …

GlaxoSmithKline's London headquarters

GSK ends neuroscience research alliance

GlaxoSmithKline has severed a strategic alliance formed in July 2007 with US biopharma company Targacept. …

The Gateway to Local Adoption Series

Latest content